Triple-negative breast cancer (TNBC) is an aggressive subtype of BC with a poor prognosis due to the lack of specific therapeutic targets, including human epidermal growth factor receptor 2 (HER-2) and hormone receptors, which renders treatment more challenging 13. This evidence concerns the gene ERBB2 and breast cancer.